I understand if your eyes begin to glaze over when someone starts to discuss trial design and statistics, but just as it is important that we know about the drugs we are getting, it is equally important that we know about trials we are getting. Proper trial design and proper rendering of the results can change and save lives.
I have posted the first of my three part interview done at ASH 2014 with Professor Hillmen on the UK’s trial acceleration programme on the CLL Society website: cllsociety.org . Part 2 and 3 will be posted on Wednesday and Friday this week or you can visit my blog bkoffman.blogspot.com for just a bit more of my commentary and a direct link.
We are all in this together.